Loading
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Previous close
$31.68
−$0.32 · -1.00%
After-hours
$32.99
+$1.31 · +4.14%
Sep 14, 4:02 PM ET
Regular session · ET · Market data may be delayed.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Day range
Current $31.68
52-week range
Current $31.68
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
45
Elevated Risk
Momentum
79
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Day range
Current $31.68
52-week range
Current $31.68
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 210K USD |
| Cost of goods sold | 661K USD | 502K USD | — | 342K USD | 145K USD |
| Gross profit | −661K USD | −502K USD | — | −342K USD | 65K USD |
| Research and development | 45.62M USD | 47M USD | 30.29M USD | 23.69M USD | 8.37M USD |
| Selling, general, and administrative | 20.75M USD | 21.61M USD | 7.52M USD | 5.16M USD | 3.75M USD |
| Operating expenses | 65.7M USD | 68.11M USD | 37.81M USD | 28.85M USD | 12.12M USD |
| Interest income | 6.6M USD | 8.85M USD | 2.35M USD | 114K USD | 2K USD |
| Interest expense | 2.47M USD | −1.38M USD | 1.37M USD | — | — |
| Depreciation and amortization | 661K USD | 502K USD | 373K USD | 342K USD | 145K USD |
| Operating income | −66.36M USD | −68.61M USD | −37.81M USD | −29.19M USD | −12.06M USD |
| Net income | −63.24M USD | −61.43M USD | −36.31M USD | −27.71M USD | −9.19M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$37.40
18.06% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI27.39M0.00%2.3T USD0.03%$374.68-0.43%
iShares Russell 2000 ETFIWM21.99M0.03%78.38B USD0.19%$287.91-0.34%
Vanguard Extended Market ETFVXF9.4M0.01%93.7B USD0.05%$236.92-0.35%
State Street SPDR S&P Pharmaceuticals ETFXPH8.97M1.52%588.06M USD0.35%$67.90+0.58%
iShares Biotechnology ETFIBB8.64M0.08%10.34B USD0.44%$204.6+0.82%
iShares Russell 2000 Growth ETFIWO7.82M0.05%14.39B USD0.24%$365.6-0.55%
Vanguard Russell 2000 ETFVTWO3.97M0.02%17.4B USD0.06%$116.37-0.33%
iShares Micro-Cap ETFIWC2.85M0.20%1.44B USD0.60%$190.92+0.04%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
